Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes

Overview

Journal J Diabetes Res

Publisher Wiley

Specialty Endocrinology

Date 2020 Aug 1

PMID 32733968

Citations 11

Authors

Yingjie Wu

An Zhou

Li Tang

Yuanyuan Lei

Bo Tang

Linjing Zhang

Affiliations

Soon will be listed here.

Abstract

Type 2 diabetes mellitus (T2DM), characterized by insulin resistance and unclear pathogenesis, is a serious menace to human health. Bile acids are the end products of cholesterol catabolism and play an important role in maintaining cholesterol homeostasis. Furthermore, increasing studies suggest that bile acids may regulate glucose tolerance, insulin sensitivity, and energy metabolism, suggesting that bile acids may represent a potential therapeutic target for T2DM. This study summarizes the metabolism of bile acids and, more importantly, changes in their concentrations, constitution, and receptors in diabetes. Furthermore, we provide an overview of the mechanisms underlying the role of bile acids in glucose and lipid metabolism, as well as the occurrence and development of T2DM. Bile acid-targeted therapy may represent a valid approach for T2DM treatment.

Citing Articles

Characterization of insulin and bile acid complexes in liposome by different mass spectrometry techniques.

Sha D, Yuan M, Zhang L, Li H Anal Bioanal Chem. 2025; 417(8):1635-1647.

PMID: 39870873 DOI: 10.1007/s00216-025-05753-y.

Untargeted metabolomic profiling reveals molecular signatures associated with type 2 diabetes in Nigerians.

Doumatey A, Shriner D, Zhou J, Lei L, Chen G, Oluwasola-Taiwo O Genome Med. 2024; 16(1):38.

PMID: 38444015 PMC: 10913364. DOI: 10.1186/s13073-024-01308-5.

Research progress on the relationship between bile acid metabolism and type 2 diabetes mellitus.

Hou Y, Zhai X, Wang X, Wu Y, Wang H, Qin Y Diabetol Metab Syndr. 2023; 15(1):235.

PMID: 37978556 PMC: 10656899. DOI: 10.1186/s13098-023-01207-6.

The relationship between bile acids levels and the prognosis of patients with diabetes on maintenance hemodialysis: a retrospective study.

Li B, Peng C, Wang Y, Ma R, Feng Y Ren Fail. 2023; 45(1):2226221.

PMID: 37340970 PMC: 10286666. DOI: 10.1080/0886022X.2023.2226221.

The Mechanism of Important Components in Canine Fecal Microbiota Transplantation.

Li K, Yang J, Zhou X, Wang H, Ren Y, Huang Y Vet Sci. 2022; 9(12).

PMID: 36548856 PMC: 9786814. DOI: 10.3390/vetsci9120695.

References

Kaur A, Patankar J, de Haan W, Ruddle P, Wijesekara N, Groen A . Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes. 2014; 64(4):1168-79. DOI: 10.2337/db14-0716. View

Ferrell J, Chiang J . Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets. Diabetes Metab J. 2019; 43(3):257-272. PMC: 6581552. DOI: 10.4093/dmj.2019.0043. View

Donepudi A, Boehme S, Li F, Chiang J . G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. Hepatology. 2016; 65(3):813-827. PMC: 5195921. DOI: 10.1002/hep.28707. View

Ding L, Sousa K, Jin L, Dong B, Kim B, Ramirez R . Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice. Hepatology. 2016; 64(3):760-73. PMC: 4992413. DOI: 10.1002/hep.28689. View

Haeusler R, Pratt-Hyatt M, Welch C, Klaassen C, Accili D . Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab. 2011; 15(1):65-74. PMC: 3253887. DOI: 10.1016/j.cmet.2011.11.010. View

Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M . A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003; 278(11):9435-40. DOI: 10.1074/jbc.M209706200. View

Kim K, Choi S, Zhou Y, Kim E, Lee J, Saha P . Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice. Hepatology. 2017; 66(2):498-509. PMC: 8156739. DOI: 10.1002/hep.29199. View

. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011; 35 Suppl 1:S64-71. PMC: 3632174. DOI: 10.2337/dc12-s064. View

Swanson H, Wada T, Xie W, Renga B, Zampella A, Distrutti E . Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab Dispos. 2012; 41(1):1-11. PMC: 3533426. DOI: 10.1124/dmd.112.048694. View

10.

Sayin S, Wahlstrom A, Felin J, Jantti S, Marschall H, Bamberg K . Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17(2):225-35. DOI: 10.1016/j.cmet.2013.01.003. View

11.

Beysen C, Murphy E, Deines K, Chan M, Tsang E, Glass A . Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2011; 55(2):432-42. DOI: 10.1007/s00125-011-2382-3. View

12.

Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk T, Grefhorst A, Abdelkarim M . The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006; 281(16):11039-49. DOI: 10.1074/jbc.M510258200. View

13.

Makishima M, Okamoto A, REPA J, Tu H, Learned R, Luk A . Identification of a nuclear receptor for bile acids. Science. 1999; 284(5418):1362-5. DOI: 10.1126/science.284.5418.1362. View

14.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402(6762):656-60. DOI: 10.1038/45230. View

15.

Slatis K, Gafvels M, Kannisto K, Ovchinnikova O, Paulsson-Berne G, Parini P . Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res. 2010; 51(11):3289-98. PMC: 2952569. DOI: 10.1194/jlr.M009308. View

16.

Berrabah W, Aumercier P, Gheeraert C, Dehondt H, Bouchaert E, Alexandre J . Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). Hepatology. 2013; 59(5):2022-33. DOI: 10.1002/hep.26710. View

17.

Schauer P, Bhatt D, Kirwan J, Wolski K, Brethauer S, Navaneethan S . Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med. 2014; 370(21):2002-13. PMC: 5451259. DOI: 10.1056/NEJMoa1401329. View

18.

Chavez-Talavera O, Tailleux A, Lefebvre P, Staels B . Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2017; 152(7):1679-1694.e3. DOI: 10.1053/j.gastro.2017.01.055. View

19.

Lee W, Chen C, Chong K, Lee Y, Chen S, Lee S . Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis. 2011; 7(6):683-90. DOI: 10.1016/j.soard.2011.07.009. View

20.

Huang H, Chen C . Alpha-melanocyte stimulating hormone in ghrelin-elicited feeding and gut motility. J Chin Med Assoc. 2019; 82(2):87-91. DOI: 10.1097/JCMA.0000000000000007. View